Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,954 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Revision of diagnostic guidelines for Kawasaki disease (6th revised edition).
Kobayashi T, Ayusawa M, Suzuki H, Abe J, Ito S, Kato T, Kamada M, Shiono J, Suda K, Tsuchiya K, Nakamura T, Nakamura Y, Nomura Y, Hamada H, Fukazawa R, Furuno K, Matsuura H, Matsubara T, Miura M, Takahashi K. Kobayashi T, et al. Among authors: suzuki h. Pediatr Int. 2020 Oct;62(10):1135-1138. doi: 10.1111/ped.14326. Epub 2020 Oct 1. Pediatr Int. 2020. PMID: 33001522 No abstract available.
JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease.
Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, Tsuda E, Nakajima H, Matsuura H, Ikeda K, Nishigaki K, Suzuki H, Takahashi K, Suda K, Kamiyama H, Onouchi Y, Kobayashi T, Yokoi H, Sakamoto K, Ochi M, Kitamura S, Hamaoka K, Senzaki H, Kimura T; Japanese Circulation Society Joint Working Group. Fukazawa R, et al. Among authors: suzuki h. Circ J. 2020 Jul 22;84(8):1348-1407. doi: 10.1253/circj.CJ-19-1094. Epub 2020 Jul 8. Circ J. 2020. PMID: 32641591 Free article. Review. No abstract available.
Variations in ORAI1 Gene Associated with Kawasaki Disease.
Onouchi Y, Fukazawa R, Yamamura K, Suzuki H, Kakimoto N, Suenaga T, Takeuchi T, Hamada H, Honda T, Yasukawa K, Terai M, Ebata R, Higashi K, Saji T, Kemmotsu Y, Takatsuki S, Ouchi K, Kishi F, Yoshikawa T, Nagai T, Hamamoto K, Sato Y, Honda A, Kobayashi H, Sato J, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Yoshiyama M, Miyashita R, Murata Y, Fujino A, Ozaki K, Kawasaki T, Abe J, Seki M, Kobayashi T, Arakawa H, Ogawa S, Hara T, Hata A, Tanaka T. Onouchi Y, et al. Among authors: suzuki h. PLoS One. 2016 Jan 20;11(1):e0145486. doi: 10.1371/journal.pone.0145486. eCollection 2016. PLoS One. 2016. PMID: 26789410 Free PMC article.
A genome-wide association study identifies three new risk loci for Kawasaki disease.
Onouchi Y, Ozaki K, Burns JC, Shimizu C, Terai M, Hamada H, Honda T, Suzuki H, Suenaga T, Takeuchi T, Yoshikawa N, Suzuki Y, Yasukawa K, Ebata R, Higashi K, Saji T, Kemmotsu Y, Takatsuki S, Ouchi K, Kishi F, Yoshikawa T, Nagai T, Hamamoto K, Sato Y, Honda A, Kobayashi H, Sato J, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Murata Y, Sasago K, Takahashi A, Kamatani N, Kubo M, Tsunoda T, Hata A, Nakamura Y, Tanaka T; Japan Kawasaki Disease Genome Consortium; US Kawasaki Disease Genetics Consortium. Onouchi Y, et al. Among authors: suzuki h, suzuki y. Nat Genet. 2012 Mar 25;44(5):517-21. doi: 10.1038/ng.2220. Nat Genet. 2012. PMID: 22446962
Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Honda T, Onouchi Y, Terai M, Hata A. Hamada H, et al. Among authors: suzuki h, suzuki y. Cytokine. 2012 Dec;60(3):681-5. doi: 10.1016/j.cyto.2012.08.006. Epub 2012 Sep 1. Cytokine. 2012. PMID: 22944461 Clinical Trial.
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: suzuki h. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease.
Nakashima Y, Sakai Y, Mizuno Y, Furuno K, Hirono K, Takatsuki S, Suzuki H, Onouchi Y, Kobayashi T, Tanabe K, Hamase K, Miyamoto T, Aoyagi R, Arita M, Yamamura K, Tanaka T, Nishio H, Takada H, Ohga S, Hara T. Nakashima Y, et al. Among authors: suzuki h. Cardiovasc Res. 2021 Jan 1;117(1):96-108. doi: 10.1093/cvr/cvz305. Cardiovasc Res. 2021. PMID: 31782770
Neoplasms in three patients following Kawasaki disease.
Suzuki H, Takeuchi T, Minami T, Shima Y, Iwahashi S, Shibuta S, Uemura S, Kounami S, Aoyagi N, Yoshikawa N. Suzuki H, et al. Pediatr Int. 2005 Apr;47(2):217-9. doi: 10.1111/j.1442-200x.2005.02028.x. Pediatr Int. 2005. PMID: 15852529 No abstract available.
14,954 results
You have reached the last available page of results. Please see the User Guide for more information.